Distributed by: MANA PHARMA, S.L.

Email: pedidos@manapharma.net
Phone: +34 910 684 450
manapharma.net

MANA PHARMA

Catalogue

MANA PHARMA

COMMITTED TO HEALTH, WITHOUT BORDERS

PROPRIETARY MEDICINES

Biocoryl®

PROCAINAMIDE HIDROCHLORIDE
Malignant ventricular arrhythmias

Procainamide (BIOCORYL) is a Class Ia antiarrhythmic medication used to treat rapid heart rhythms (tachycardias), including those associated with WPW Syndrome. It is valued in hospital settings for its fast action and minimal impact on heart muscle function.

Clinical evidence demonstrates high effectiveness and a strong safety profile. The PROCAMIO trial showed that procainamide was more successful at stopping arrhythmias (67% vs. 38%) and resulted in far fewer side effects (9% vs. 41%) than amiodarone. Other studies confirm its superior success rates compared to alternative treatments.

Offering rapid rhythm control with fewer complications than amiodarone, procainamide is a cost-efficient, well-tolerated, and rapid first-line option for emergency arrhythmia management.

INTRAVENOUS
ANTICUDE®
EDROPHONIUM BROMIDE

EDROPHONIUM BROMIDE
Myasthenia gravis

Edrophonium bromide (ANTICUDE) is a short-acting anticholinesterase used to diagnose myasthenia gravis (MG) and distinguish myasthenic from cholinergic crises. Its rapid onset and brief duration make it ideal for diagnostic use requiring quick, reversible results.

Under monitored conditions, serious reactions are rare, and its short action enhances safety compared to longer-acting agents.

ANTICUDE stands out for its speed, specificity, and safety, offering a reliable, low-risk diagnostic tool for MG and other critical care applications needing fast, accurate testing.

UROKINASE

UROKINASE
Thrombosed catheters

Urokinase is a human-derived enzyme that converts plasminogen into plasmin, dissolving fibrin clots and restoring catheter function. It plays a key role in managing thrombotic occlusions in dialysis, oncology, and intensive care, where maintaining vascular access is essential.

Clinical evidence shows up to 73% success with a single dose and flow restoration within 30–60 minutes, with few adverse effects.

In addition to proven efficacy and safety, urokinase reduces the need for re-interventions, catheter replacements, and hospital stays, offering a cost-effective and reliable option for vascular access management.

Vinpocetine

covex

Vinpocetine is a semi-synthetic derivative of vincamine (an ethyl ester of apovincamine) with proposed multimodal cerebrovascular and neuroprotective actions: vasodilation, inhibition of PDE1, modulation of Na+ channels, anti-oxidant and anti-inflammatory effects, and improved neuronal metabolism.

In acute ischemic stroke, clinical data from randomized trials suggest vinpocetine may reduce mortality and disability while improving cognitive and motor outcomes, with a favorable safety profile.

Its main differentiator lies in its multi-target mechanism, combining vascular, metabolic, and neuroprotective benefits in one compound.

VINCAMINE



VINBURNINE